Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection
NCT ID: NCT02933905
Last Updated: 2016-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
38 participants
OBSERVATIONAL
2014-01-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser
NCT03590444
Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema
NCT04089605
Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular Edema
NCT03603990
Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.
NCT03458923
Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema
NCT02059772
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non-PVD subjects
Patients with no PVD on SD-OCT at basal visit
Intravitreal Ranibizumab injection
PVD subjects
Patients with PVD on SD-OCT at basal visit
Intravitreal Ranibizumab injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intravitreal Ranibizumab injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* cardiovascular events during the last year
* previous vitrectomy
* previous macular edema treatment during the last 4 months
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundació Institut Germans Trias i Pujol
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xavier Valldeperas
MD, PhD, FEBO
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OFT-RAN-2013-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.